Loading…
Employees: 382
Size Nxera Pharma (4565.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $932M, the 761st largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,587 on 6 Nov 2026.
Performance Over six months the shares gained 63.4%, against -16.2% for the median peer and +1.8% for the Japan market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 23.7% over the last twelve months (peer median +1.0%); the operating margin is 13.6% (peer median 2.5%).
Valuation It trades at 24.5× forward earnings against a peer median of 27.5× (3rd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.9 points below its cost of capital (5.3% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥35.5B | ¥29.6B | ¥28.8B | ¥12.8B | ¥15.6B |
| Revenue growth | — | +3% | +126% | -18% | — |
| Gross profit | ¥28.1B | ¥18.0B | ¥18.1B | ¥7.87B | ¥13.8B |
| EBITDA | ¥9.17B | -¥3.71B | -¥1.38B | -¥6.58B | ¥4.16B |
| Net income | -¥5.39B | -¥12.5B | -¥4.84B | -¥7.19B | ¥382M |
| Free cash flow | ¥5.01B | -¥3.12B | -¥8.24B | -¥6.08B | ¥9.68B |
| Capital expenditure | ¥5.85B | ¥625M | ¥1.54B | ¥851M | ¥303M |
| Total debt | ¥52.0B | ¥57.4B | ¥67.9B | ¥74.0B | ¥29.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4565.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.7% | -9.0% | highest of 20 |
| 6-month return | +63.4% | -16.2% | highest of 20 |
| Distance from 52-week high | -13.0% | -33.9% | 2nd highest of 21 |
| Revenue growth (TTM) | +23.7% | +1.0% | 2nd highest of 18 |
| Operating margin | 13.6% | 2.5% | 5th highest of 18 |
| Forward P/E | 24.5× | 27.5× | 3rd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | 16.2% | 16.2% | 4th least demanding of 8 |
| Growth delivered (Del g) | +27.3% | +4.2% | 2nd highest of 8 |
| Hurdle (Req g minus delivered) | -11.2 pp | +10.3 pp | least demanding of 8 |
| ROIC minus cost of capital | -1.9 pp | -3.2 pp | 4th highest of 17 |
| EV / EBITDA | 19.9× | 19.0× | 3rd most expensive of 7 |
| Net debt / EBITDA | 3.9× | 1.8× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 27.5× | 16.7% | +27.7% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 12.0× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 15.5× | 18.1% | +7.8% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | n/a | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | n/a | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |